329 related articles for article (PubMed ID: 24041138)
21. Prevalence and correlates of cardiovascular medication use among nursing home residents with ischemic heart disease: results from the SHELTER study.
Foebel AD; Liperoti R; Gambassi G; Gindin J; Ben Israel J; Bernabei R; Onder G
J Am Med Dir Assoc; 2014 Jun; 15(6):410-5. PubMed ID: 24559641
[TBL] [Abstract][Full Text] [Related]
22. Angiotensin receptor blockers: powerful evidence with cardiovascular outcomes?
Pourdjabbar A; Lapointe N; Rouleau JL
Can J Cardiol; 2002 May; 18 Suppl A():7A-14A. PubMed ID: 12045788
[TBL] [Abstract][Full Text] [Related]
23. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system.
Toh S; Reichman ME; Houstoun M; Ross Southworth M; Ding X; Hernandez AF; Levenson M; Li L; McCloskey C; Shoaibi A; Wu E; Zornberg G; Hennessy S
Arch Intern Med; 2012 Nov; 172(20):1582-9. PubMed ID: 23147456
[TBL] [Abstract][Full Text] [Related]
24. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
Vijan SG
J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
[TBL] [Abstract][Full Text] [Related]
25. Outpatient management of heart failure in the United States, 2006-2008.
Mosalpuria K; Agarwal SK; Yaemsiri S; Pierre-Louis B; Saba S; Alvarez R; Russell SD
Tex Heart Inst J; 2014 Jun; 41(3):253-61. PubMed ID: 24955039
[TBL] [Abstract][Full Text] [Related]
26. Ten-year trends of cardiovascular drug use after myocardial infarction among community-dwelling persons > or =65 years of age.
Setoguchi S; Glynn RJ; Avorn J; Levin R; Winkelmayer WC
Am J Cardiol; 2007 Oct; 100(7):1061-7. PubMed ID: 17884362
[TBL] [Abstract][Full Text] [Related]
27. A survey of outpatient management of elderly heart failure patients in Poland-treatment patterns.
Rywik TM; Rywik SL; Korewicki J; Broda G; Sarnecka A; Drewla J
Int J Cardiol; 2004 Jun; 95(2-3):177-84. PubMed ID: 15193817
[TBL] [Abstract][Full Text] [Related]
28. Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta-blockers in patients hospitalized for acute heart failure.
Carubelli V; Lombardi C; Specchia C; Peveri G; Oriecuia C; Tomasoni D; Di Pasquale M; Inciardi R; Garrafa E; Metra M
ESC Heart Fail; 2021 Jun; 8(3):1944-1953. PubMed ID: 33660949
[TBL] [Abstract][Full Text] [Related]
29. Treatment prescription, adherence, and persistence after the first hospitalization for heart failure: A population-based retrospective study on 100785 patients.
Scalvini S; Bernocchi P; Villa S; Paganoni AM; La Rovere MT; Frigerio M
Int J Cardiol; 2021 May; 330():106-111. PubMed ID: 33582198
[TBL] [Abstract][Full Text] [Related]
30. Impact of restrictive prescription plans on heart failure medication use.
Thanassoulis G; Karp I; Humphries K; Tu JV; Eisenberg MJ; Pilote L
Circ Cardiovasc Qual Outcomes; 2009 Sep; 2(5):484-90. PubMed ID: 20031881
[TBL] [Abstract][Full Text] [Related]
31. [Guideline compliance in the treatment of patients with chronic heart failure through family doctor-centred health care: results of an evaluation study].
Roehl I; Beyer M; Gondan M; Rochon J; Bauer E; Kaufmann-Kolle P; Gerlach FM
Z Evid Fortbild Qual Gesundhwes; 2013; 107(6):394-402. PubMed ID: 24075681
[TBL] [Abstract][Full Text] [Related]
32. Possible ways to enhance renin-angiotensin prescribing efficiency: Republic of Serbia as a case history?
Kalaba M; Godman B; Vuksanović A; Bennie M; Malmström RE
J Comp Eff Res; 2012 Nov; 1(6):539-49. PubMed ID: 24236473
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in chronic allograft injury.
Shah PR; Kute VB; Saboo DS; Goplani KR; Gumber MR; Vanikar AV; Patel HV; Trivedi HL
Saudi J Kidney Dis Transpl; 2011 Nov; 22(6):1128-32. PubMed ID: 22089769
[TBL] [Abstract][Full Text] [Related]
34. Nonadherence to angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers among high-risk patients with diabetes in Medicare Part D programs.
Yang Y; Thumula V; Pace PF; Banahan BF; Wilkin NE; Lobb WB
J Am Pharm Assoc (2003); 2010; 50(4):527-31. PubMed ID: 20621872
[TBL] [Abstract][Full Text] [Related]
35. Change in prescription pattern as a potential marker for adverse drug reactions of angiotensin converting enzyme inhibitors.
Mahmoudpour SH; Asselbergs FW; de Keyser CE; Souverein PC; Hofman A; Stricker BH; de Boer A; Maitland-van der Zee AH
Int J Clin Pharm; 2015 Dec; 37(6):1095-103. PubMed ID: 26159317
[TBL] [Abstract][Full Text] [Related]
36. Relationship Between Medical Therapy, Long-Term Care Insurance, and Comorbidity in Elderly Patients With Heart Failure With Systolic Dysfunction.
Kase M; Fujiki S; Kashimura T; Okura Y; Kodera K; Watanabe H; Takahashi K; Bannai S; Hatano T; Tanaka T; Kitamura N; Minamino T; Inomata T
Circ J; 2023 Jul; 87(8):1130-1137. PubMed ID: 36928271
[TBL] [Abstract][Full Text] [Related]
37. Underutilization of angiotensin converting enzyme inhibitors among heart failure patients.
Lean QY; Shamsuddin N; Wan Ahmad WA
Med J Malaysia; 2008 Aug; 63(3):216-21. PubMed ID: 19248693
[TBL] [Abstract][Full Text] [Related]
38. Incremental cost-effectiveness of guideline-directed medical therapies for heart failure.
Banka G; Heidenreich PA; Fonarow GC
J Am Coll Cardiol; 2013 Apr; 61(13):1440-6. PubMed ID: 23433562
[TBL] [Abstract][Full Text] [Related]
39. Treatment with renin-angiotensin system inhibitors and prognosis of heart failure with preserved ejection fraction: A propensity-matched study in the community.
Egido JJ; Gomez R; Romero SP; Andrey JL; Ramirez D; Rodriguez A; Pedrosa MJ; Gomez F
Int J Clin Pract; 2019 Jun; 73(6):e13317. PubMed ID: 30694579
[TBL] [Abstract][Full Text] [Related]
40. A review of heart failure management in the elderly population.
Cheng JW; Nayar M
Am J Geriatr Pharmacother; 2009 Oct; 7(5):233-49. PubMed ID: 19948300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
